DOC shares rise 13.5% in a month as lab demand, senior care growth and $925M in deals highlight its capital strategy.
Healthpeak Properties has concentrated exposure to South San Francisco life-science assets, allowing it to benefit from the region's innovation-led recovery without relying on downtown office demand. DOC's portfolio is diversified nationally, with 23% of NOI coming from San Francisco while Outpatient Medical assets provide the majority of stable cash flow. The portfolio has a 7.3-year average lease term, with longer Outpatient Medical leases providing stability and shorter Lab leases allowing faster adjustment as leasing conditions improve.
DOC aims to unlock value in its senior housing platform by spinning out Janus Living via an IPO while retaining control and recurring management income.
Healthpeak Properties remains a contrarian, long-term opportunity, with management focused on capital allocation, a covered dividend, and technology-driven efficiencies. DOC plans to recycle $1B+ from outpatient medical asset sales into higher-return lab assets, targeting double-digit unlevered IRRs despite near-term sector headwinds. Lab and outpatient segments show improving leasing pipelines, with occupancy expected to bottom in the high 70s before recovery, while CCRC delivers strong NOI growth.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
At the start of the new year, investors seeking a fresh approach might consider stocks that are positioned for a reset. Companies trading at or near their lowest level for 2025 could be primed for gains in the new year if conditions are right.
The September inflation reading of 3% represents moderate price growth, which is above the Federal Reserve's long-term target of 2% but well below the elevated rates seen in 2022 and early 2023.
Healthpeak Properties is deeply undervalued, trading at just 9.1x forward P/FFO and offering a 7.3% dividend yield. DOC benefits from strong fundamentals in outpatient medical and senior housing, with same-store NOI growth and robust re-leasing spreads. Management is executing $1 billion in asset sales, tightening cost controls, and targeting double-digit unlevered IRRs on new investments.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
Healthpeak Properties maintains a Buy rating, offering a ~6.7% sustainable monthly dividend yield and strong potential for recovery as industry headwinds could ease. DOC reported robust Q3 results, with solid AFFO, solid asset recycling, conservative balance sheet management, and a significant pipeline for higher-return lab investments. Near-term catalysts include the Fed's rate cuts and asset recycling advancing, while macro uncertainty and lab occupancy declines may cause short-term volatility for DOC.
All of us could benefit from a little extra income every month, and many dividend investors look for passive income through dividend stocks.